Results 251 to 260 of about 15,828 (290)

Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets

Blood, 2002
Abstract Thrombocytopenia, often severe, occurs in 1% to 2% of patients given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine specificity-determining and human framework sequences. The cause of this complication has not yet been defined. Studies of 9 patients who developed profound thrombocytopenia
Richard H. Aster, Janice G. McFarland, Julia Swyers, Brian R. Curtis, Ajit Divgi   +4 more
openaire   +3 more sources

Potential Anaphylactic Shock with Abciximab Readministration

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
A 46‐year‐old woman developed an anaphylactic reaction during percutaneous coronary intervention after she was pretreated with prednisone and diphenhydramine for a known allergy to iodine. She developed pruritus, edema, and nausea, which were followed by bradycardia and shock, minutes after administration of a bolus and standard‐dose infusion of ...
Donald A. Palisaitis, Denis Hamel, Chantal Pharand   +2 more
openaire   +3 more sources

Delayed thrombocytopenia following abciximab therapy

International Journal of Cardiovascular Interventions, 2001
Inhibitors of glycoprotein (GP) IIb/IIIa are currently approved for the treatment of acute coronary syndromes and during performance of percutaneous coronary interventions (PCIs). More than 500 000 patients annually undergo PCIs in the USA alone. Of these, 35% are receiving GPIIb/IIIa inhibitors.
Inna Khiger, Gad Cotter, Edo Kaluski, Marina Leitman   +3 more
openaire   +3 more sources

Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.

EuroIntervention, 2014
AIMS In recent years, intracoronary bolus abciximab has emerged as an alternative to the standard intravenous route in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
R. Piccolo, I. Eitel, A. Iversen, Youlan L. Gu, A. Domínguez-Rodríguez, B. D. de Smet, K. Mahmoud, P. Abreu-González, H. Thiele, F. Piscione   +9 more
semanticscholar   +1 more source

Understanding the complexity of abciximab-related thrombocytopenia

Thrombosis and Haemostasis, 2010
Patients with a rare bleeding disorder characterised by skin and mucosal bleeding – typical of thrombocytopenia – but with a normal platelet count, and later characterised by a defective aggregation to all agonists, described as Glanzmann thrombasthenia, have mutations in a platelet membrane glycoprotein (GP) called GP IIb/IIIa, also known as the ...
De Caterina R, Zimarino M.
openaire   +5 more sources

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Journal of the American Medical Association (JAMA), 2006
CONTEXT No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after ...
A. Kastrati, J. Mehilli, F. Neumann, F. Dotzer, J. T. ten Berg, H. Bollwein, Isolde Graf, Maryam Ibrahim, J. Pache, M. Seyfarth, H. Schühlen, J. Dirschinger, P. Berger, A. Schömig   +13 more
semanticscholar   +1 more source

Trombocitopenia extrema secundaria a abciximab [PDF]

Revista Española de Cardiología, 2004
Los antiagregantes antiglucoproteina IIb/IIIa bloquean la union del fibrinogeno y el factor de Von Willebrand a sus receptores. Pueden causar hemorragia y trombocitopenia. Se ha analizado la incidencia y la repercusion clinica de la trombocitopenia extrema severa (< 20.000 por µl) secundaria a abciximab en un estudio prospectivo de 375 pacientes (el 74%
Dolores M. Arias Garcia, José Luis Castillo Castro, Miguel A. Prieto Palomino, Rocio M. Aragones Manzanares, Manuel Delgado Amaya, Juan A. Bullones Ramirez   +5 more
openaire   +1 more source

Treatment of radial artery occlusions using balloon angioplasty and localized intra-arterial abciximab.

Journal of interventional cardiology, 2014
OBJECTIVES To study an alternative strategy for the treatment of radial artery occlusion (RAO) using balloon angioplasty and intrathrombus administration of abciximab. BACKGROUND RAO is a well-described complication of transradial procedures.
Z. Jaradat, Babar B. Basir, G. Revtyak
semanticscholar   +1 more source

Visual compatibility of abciximab with selected drugs

American Journal of Health-System Pharmacy, 2002
(March 1, 2002, Letter). In the table on page 466, the concentration of fentanyl citrate should be 0.05 mg/mL.
Steven Baroletti, William W. Churchill, Christian Hartman   +2 more
openaire   +3 more sources

Alveolar Hemorrhage as a Complication of Treatment With Abciximab

Chest, 2001
The use of abciximab, a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, is associated with improved outcome after angioplasty and stent placement. Major complications include bleeding, but pulmonary hemorrhage has been reported rarely.
Malcolm R. Bell, Sanjay Kalra, Charanjit S. Rihal   +2 more
openaire   +3 more sources